RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
GeneReach Biotechnology Stock

GeneReach Biotechnology Revenue 2024

GeneReach Biotechnology Revenue

225.46 M TWD

Ticker

4171.TWO

ISIN

TW0004171004

In 2024, GeneReach Biotechnology's sales reached 225.46 M TWD, a -69.94% difference from the 750.02 M TWD sales recorded in the previous year.

The GeneReach Biotechnology Revenue history

YEARREVENUE (undefined TWD)GROSS MARGIN (%)
20230.2312,23
20220.7565,34
20211.0173,81
20200.8674,14
20190.3782,57
20180.1979,69
20170.1680,70
20160.1580,74
20150.1578,91
20140.1380,23
20130.168,90
20120.178,14
20110.1183,62
20100.0888,70
20090.0686,77

GeneReach Biotechnology Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into GeneReach Biotechnology, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by GeneReach Biotechnology from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects GeneReach Biotechnology’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of GeneReach Biotechnology. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into GeneReach Biotechnology’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing GeneReach Biotechnology’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on GeneReach Biotechnology’s growth potential.

GeneReach Biotechnology Revenue, EBIT and net profit per share

DateGeneReach Biotechnology RevenueGeneReach Biotechnology EBITGeneReach Biotechnology Net Income
2023225.46 M undefined-229.29 M undefined-166.27 M undefined
2022750.02 M undefined241.34 M undefined221.34 M undefined
20211.01 B undefined482.35 M undefined376.62 M undefined
2020857.03 M undefined355.41 M undefined257.28 M undefined
2019365.8 M undefined111.94 M undefined77.18 M undefined
2018187.42 M undefined11.38 M undefined28.57 M undefined
2017155.41 M undefined-21.42 M undefined-48.13 M undefined
2016150.27 M undefined-26.68 M undefined-38.66 M undefined
2015149.15 M undefined-26.95 M undefined-24.82 M undefined
2014133.65 M undefined-42.26 M undefined-30.43 M undefined
201395.85 M undefined-57.83 M undefined-58 M undefined
201299.58 M undefined-31.1 M undefined-23.35 M undefined
2011105.6 M undefined3.87 M undefined3.54 M undefined
201082.18 M undefined16.22 M undefined13.04 M undefined
200962.65 M undefined5.55 M undefined4.54 M undefined

GeneReach Biotechnology stock margins

The GeneReach Biotechnology margin analysis displays the gross margin, EBIT margin, as well as the profit margin of GeneReach Biotechnology. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for GeneReach Biotechnology.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the GeneReach Biotechnology's sales revenue. A higher gross margin percentage indicates that the GeneReach Biotechnology retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the GeneReach Biotechnology's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the GeneReach Biotechnology's total revenue generated. When comparing the revenue margin year over year, investors can gauge the GeneReach Biotechnology's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the GeneReach Biotechnology. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the GeneReach Biotechnology's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

GeneReach Biotechnology Margin History

GeneReach Biotechnology Gross marginGeneReach Biotechnology Profit marginGeneReach Biotechnology EBIT marginGeneReach Biotechnology Profit margin
202312.23 %-101.7 %-73.75 %
202265.34 %32.18 %29.51 %
202173.81 %47.66 %37.21 %
202074.14 %41.47 %30.02 %
201982.57 %30.6 %21.1 %
201879.69 %6.07 %15.24 %
201780.7 %-13.78 %-30.97 %
201680.74 %-17.75 %-25.73 %
201578.91 %-18.07 %-16.64 %
201480.23 %-31.62 %-22.77 %
201368.9 %-60.33 %-60.52 %
201278.14 %-31.23 %-23.45 %
201183.62 %3.67 %3.35 %
201088.7 %19.74 %15.87 %
200986.77 %8.86 %7.24 %

GeneReach Biotechnology Aktienanalyse

What does GeneReach Biotechnology do?

GeneReach Biotechnology ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding GeneReach Biotechnology's Sales Figures

The sales figures of GeneReach Biotechnology originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing GeneReach Biotechnology’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize GeneReach Biotechnology's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in GeneReach Biotechnology’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about GeneReach Biotechnology stock

How much revenue did GeneReach Biotechnology generate this year?

GeneReach Biotechnology has achieved a revenue of 225.46 M TWD this year.

How much was the turnover of the company GeneReach Biotechnology compared to the previous year?

The revenue of GeneReach Biotechnology has increased by -69.94% decreased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of GeneReach Biotechnology?

The revenue of GeneReach Biotechnology is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of GeneReach Biotechnology measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of GeneReach Biotechnology so important for investors?

The revenue of GeneReach Biotechnology is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does GeneReach Biotechnology pay?

Over the past 12 months, GeneReach Biotechnology paid a dividend of 1.2 TWD . This corresponds to a dividend yield of about 4.09 %. For the coming 12 months, GeneReach Biotechnology is expected to pay a dividend of 1.2 TWD.

What is the dividend yield of GeneReach Biotechnology?

The current dividend yield of GeneReach Biotechnology is 4.09 %.

When does GeneReach Biotechnology pay dividends?

GeneReach Biotechnology pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of GeneReach Biotechnology?

GeneReach Biotechnology paid dividends every year for the past 2 years.

What is the dividend of GeneReach Biotechnology?

For the upcoming 12 months, dividends amounting to 1.2 TWD are expected. This corresponds to a dividend yield of 4.09 %.

In which sector is GeneReach Biotechnology located?

GeneReach Biotechnology is assigned to the 'Health' sector.

Wann musste ich die Aktien von GeneReach Biotechnology kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of GeneReach Biotechnology from 9/4/2023 amounting to 1.2 TWD, you needed to have the stock in your portfolio before the ex-date on 7/28/2023.

When did GeneReach Biotechnology pay the last dividend?

The last dividend was paid out on 9/4/2023.

What was the dividend of GeneReach Biotechnology in the year 2023?

In the year 2023, GeneReach Biotechnology distributed 3.636 TWD as dividends.

In which currency does GeneReach Biotechnology pay out the dividend?

The dividends of GeneReach Biotechnology are distributed in TWD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von GeneReach Biotechnology

Our stock analysis for GeneReach Biotechnology Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of GeneReach Biotechnology Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.